Sep 2023 – present	MSc in Data Science and Analytics, Department of Applied Mathematics, Faculty of Computer and Mathematical Science, The Hong Kong Polytechnic University
Sep 2022 – Nov 2023	PgD in Finance and Data Analytics (with Distinction), HKU School of Professional and Continuing Education (HKU SPACE)
Sep 2017 – Dec 2022	PhD in Pharmacology (Chinese Medicine), School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong (HKU)
Sep 2014 – Jun 2017	MPhil in Chinese Medicine, Shanghai University of Traditional Chinese Medicine
Sep 2007 – Jun 2013	BSc in Chinese Medicine, Shanghai University of Traditional Chinese Medicine

Jul 2025 – Present:	Research Assistant Professor, School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong
Jan 2022 – Jun 2025	Postdoctoral Fellow, School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong
Jan 2016 – May 2017	Student Research Assistant, School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong

Research Fields

Pharmacology in Chinese Medicine; Data Science

2024	Third Prize “AI Driven Drug Exploration: A Deep Learning Based System for Pharmacodynamic Prediction”, 6th Chinese Medicine Innovation & Entrepreneurship Competition, Macau
2023	Awarded the HKU Central Pool Postdoctoral Fellowship Position for the 47th Round URC PDF/RAP Scheme (PI: Prof. Yibin Feng, HKU)
2023	Excellence Prize “Intelligent Drug Discovery: A Chemometrics Characterization Prediction System Driven by Deep Neural Networks”, 5th Chinese Medicine Innovation & Entrepreneurship Competition, Macau
2020	Youth Outstanding Thesis Award “Geniposide inhibits the TLR4/MyD88 pathway for suppressing HIF-1alpha-independent VEGF expression and angiogenesis in hepatocellular carcinoma”, 16th International Postgraduate Symposium on Chinese Medicine, Hong Kong
2020	KAN Shin Yu Chinese Medicine Postgraduate Research Prize, HKU
2019	Youth Outstanding Thesis Award “A Novel Mathematic-Biological Evaluation Approach for identifying Contributive Compounds in Herbal Medicines”, 15th International Postgraduate Symposium on Chinese Medicine, Hong Kong
2018	KAN Shin Yu Chinese Medicine Postgraduate Research Prize, HKU

Books

Editorial Member

“Anti-Cancer Chinese Medicines: Modern Research and Clinical Application”,
Editor-in-Chief by. Feng Y., Xu H., Zhu G.;
Shanghai Science and Technology Publisher (2018).

(First author papers, selected 10 papers

1. Zhang, C., Sun, TT., Lv, Y., Li, X., Ling, Y., Wang, N., Wen, X., Fan, XH*., Feng Y*. (2024). A Chinese herbal formula Kesuting Syrup against COVID-19: leveraging multidimensional computations in network pharmacology-driven experimental and clinical trials. Clinical and Translational Medicine, 14: e1569
2. Zhang, C., Chen, GM., Tang GY., Xu XY., Wang N., Feng, Y* et al. (2023). Multi-component Chinese medicine formulas for drug discovery: State of the art and future perspectives. Acta Materia Medica. Vol. 2(1):106-125.
3. Zhang, C., Wang, N., Chen, GM., Tan, H. Y. Feng, Y* et al. (2022). Single-cell co-expression analysis using machine learning reveals oxidative, immunopathologic, and myocardial responses for multi-organ failure in COVID-19. Clinical and Translational Medicine, 0798.
4. Zhang, C., Tam, CW, Tang, GY., Chen, YY., Feng, Y* et al. (2022). Spatial Transcriptomic Analysis Using R-Based Computational Machine Learning Reveals the Genetic Profile of Yang or Yin Deficiency Syndrome in Chinese Medicine Theory. Evidence-based Complementary and Alternative Medicine, 5503181
5. Zhang, C., Feng YG, Tam CW, Wang, N, Feng, Y*. (2021). Transcriptional profiling and machine learning unveil a concordant biosignature of Type I interferon-inducible host response across nasal swab and pulmonary tissue for COVID-19 diagnosis. Frontiers in immunology, 22, 733171.
6. Zhang, C., Wang, N., Tan, H. Y., Feng, Y*. (2021). Identification of Key Contributive Compounds in a Herbal Medicine: A Novel Mathematic-Biological Evaluation Approach. Advanced Theory and Simulations, 4, 1002.
7. Zhang, C., Wang, N., Tan, H. Y., Guo, W., Feng, Y* et al. (2020). Direct inhibition of the TLR4/MyD88 pathway by geniposide suppresses HIF-1alpha-independent VEGF expression and angiogenesis in hepatocellular carcinoma. British Journal of Pharmacology, 177(14), 3240-3257.
8. Zhang, C., Wang, N., Xu, Y., Tan, H. Y., Feng, Y* et al. (2018). Molecular Mechanisms Involved in Oxidative Stress-Associated Liver Injury Induced by Chinese Herbal Medicine: An Experimental Evidence-Based Literature Review and Network Pharmacology Study. International journal of molecular sciences, 19(9).
9. Zhang, C., Wang, N., Tan, H. Y., Guo, W., Feng, Y* et al. (2018). Targeting VEGF/VEGFRs Pathway in the Antiangiogenic Treatment of Human Cancers by Traditional Chinese Medicine. Integrative Cancer Therapies, 17(3), 582-601.
10. Zhang, C., Xu, Y., Tan, H. Y., Li, S., Wang N., Zhang YJ*., Feng, Y* et al. (2018). Neuroprotective effect of He-Ying-Qing-Re formula on retinal ganglion cell in diabetic retinopathy. Journal of Ethnopharmacology, 214, 179-189.

(Co /joint author papers, selected 30 papers)

1. Chen, G.*, Zhang, C.*, Zou, J., Zhou, Z., Zhang, J., Yan, Y., Liang, Y., Tang, G., Chen, G., Xu, X., Wang, N., & Feng, Y.* (2025). Coptidis Rhizoma and Berberine as Anti-cancer Drugs: a 10-year updates and future perspectives. Pharmacological research, 107742. (co-first author)
2. Cui, D.*, Zhang, C.*, Zhang, L.*, Zheng, J., Wang, J., He, L., Jin, H., Kang, Q., Zhang, Y., Li, N., Sun, Z., Zheng, W., Wei, J., Zhang, S., Tan, W., Feng, Y.*, & Zhong, Z* (2025). Natural Anti-Cancer Products: insights from Herbal Medicine. Chinese Medicine, 20, 82. (co-first author)
3. Xun, Y., Chen, G., Tang, G., Zhang, C., Zhou, S., Fong, T. L., Chen, Y., Xiong, R., Wang, N., & Feng, Y.* (2025). Traditional Chinese medicine and natural products in management of hepatocellular carcinoma: Biological mechanisms and therapeutic potential. Pharmacological research, 215, 107733.
4. Chen, Y., Zhang, C., & Feng, Y.* (2024). Medicinal plants for the management of post-COVID-19 fatigue: A literature review on the role and mechanisms. Journal of traditional and complementary medicine, 15(1), 15–23.
5. Miao, C, Huang, Y, Zhang, C, Wang, X, Wang, B, Zhou, X, Song, Y, Wu, P, Chen, ZS, & Feng, Y.* (2025). Post-translational modifications in drug resistance. Drug Resist Updat,78, 101173.
6. Chan, Y. T., Zhang, C, Wu, J, Lu, P, Xu, L, Yuan, H, Feng, Y, Chen, ZS, Wang, N.* (2024). Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma. Mol Cancer, 23(1), 189.
7. Wu J, Tan HY, Chan YT, Lu Y, Feng Z, Yuan H, Zhang C, Feng Y,* Wang N.* (2024). PARD3 drives tumorigenesis through activating Sonic Hedgehog signaling in tumour-initiating cells in liver cancer. J Exp Clin Cancer Res. Feb 6;43(1):42.
8. Xu X, Zhang C, Tang G, Wang N, Feng Y.* (2024). Single-cell transcriptome profiling highlights the role of APP in blood vessels in assessing the risk of patients with proliferative diabetic retinopathy developing Alzheimer's disease. Front Cell Dev Biol. Jan 24;11:1328979.
9. Chan YT, Tan HY, Lu Y, Zhang C, Cheng CS, Wu J, Wang N,* Feng Y.* (2023). Pancreatic melatonin enhances anti-tumor immunity in pancreatic adenocarcinoma through regulating tumor-associated neutrophils infiltration and NETosis. Acta Pharm Sin B,13(4):1554-67.
10. Chen G, Wang N, Yang R, Wu Y, Liu J, Huang Z, Zhang Z, Huang Y, Zhang C, Chan YT, Feng Y.* (2023). Efficacy and safety of herbal medicines intervention for cachexia associated with cancer: A systematic review and meta-analysis. Phytother Res. Nov;37(11):5243-5278.
11. Lu Y, Chan YT, Wu J, Feng Z, Yuan H, Li Q, Xing T, Xu L, Zhang C, Tan HY, Lee TK, Feng Y,* Wang N.* (2023). CRISPR/Cas9 screens unravel miR-3689a-3p regulating sorafenib resistance in hepatocellular carcinoma via suppressing CCS/SOD1-dependent mitochondrial oxidative stress. Drug Resist Updat. Nov 71:101015.
12. Wu J, Chan YT, Lu Y, Feng Z, Yuan H, Xu X, Xu L, Zhang C, Feng Y, Tan HY, Wang N.* (2023). Genipin-activating PPARγ impedes CCR2-mediated macrophage infiltration into postoperative liver to suppress recurrence of hepatocellular carcinoma. Int J Biol Sci, Oct 16;19(16):5257-5274.
13. Chen, G., Zhang, C., Li, D., Luo, D., Liao, H., Huang, P., Wang, N., & Feng, Y.* (2023). HAMP as a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma. Biomolecules, 13(2).
14. Zhong, Z., Vong, C. T., Chen, F., Tan, H., Zhang, C., Wang, N., Cui, L., Wang, Y., & Feng, Y.* (2022). Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets. Med Res Rev, 42(3), 1246-1279.
15. Lu, Y., Chan, Y. T., Tan, H. Y., Zhang, C., Guo, W., Xu, Y., Sharma, R., Chen, Z. S., Zheng, Y. C., Wang, N.,* & Feng, Y.* (2022). Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma. J Exp Clin Cancer Res, 41(1), 3.
16. Feng, Z., Wu, J., Lu, Y., Chan, Y. T., Zhang, C., Wang, D., Luo, D., Huang, Y., Feng, Y.,* & Wang, N.* (2022). Circulating tumor cells in the early detection of human cancers. Int J Biol Sci, 18(8), 3251-3265.
17. Chen, G., Luo, D., Zhong, N., Li, D., Zheng, J., Liao, H., Li, Z., Lin, X., Chen, Q., Zhang, C., Lu, Y., Chan, Y. T., Ren, Q., Wang, N., & Feng, Y.* (2022). GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer. Front Immunol, 13, 857308.
18. Chen, F., Zhong, Z., Zhang, C., Lu, Y., Chan, Y. T., Wang, N., Zhao, D., & Feng, Y.* (2022). Potential Focal Adhesion Kinase Inhibitors in Management of Cancer: Therapeutic Opportunities from Herbal Medicine. Int J Mol Sci, 23(21).
19. Wang, N., Zhang, C., Xu, Y., Tan, H. Y., Chen, H., & Feng, Y.* (2021). Berberine improves insulin-induced diabetic retinopathy through exclusively suppressing Akt/mTOR-mediated HIF-1α/VEGF activation in retina endothelial cells. Int J Biol Sci, 17(15), 4316-4326.
20. Wang, N., Wang, L., Zhang, C., Tan, H. Y., Zhang, Y., & Feng, Y.* (2021). Berberine suppresses advanced glycation end products-associated diabetic retinopathy in hyperglycemic mice. Clin Transl Med, 11(11), e569.
21. Wang, N., Tan, H. Y., Lu, Y., Chan, Y. T., Wang, D., Guo, W., Xu, Y., Zhang, C., Chen, F., Tang, G., & Feng, Y.* (2021).PIWIL1 governs the crosstalk of cancer cell metabolism and immunosuppressive microenvironment in hepatocellular carcinoma. Signal Transduct Target Ther, 6(1), 86.
22. Tang, G., Xu, Y., Zhang, C., Wang, N., Li, H., & Feng, Y.* (2021). Green Tea and Epigallocatechin Gallate (EGCG) for the Management of Nonalcoholic Fatty Liver Diseases (NAFLD): Insights into the Role of Oxidative Stress and Antioxidant Mechanism. Antioxidants (Basel), 10(7).
23. Tang, G., Li, S., Zhang, C., Chen, H., Wang, N., & Feng, Y.* (2021). Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management. Acta Pharm Sin B, 11(9), 2749-2767.
24. Tan, H. Y., Wang, N., Zhang, C., Chan, Y. T., Yuen, M. F., & Feng, Y.* (2021). Lysyl Oxidase-Like 4 Fosters an Immunosuppressive Microenvironment During Hepatocarcinogenesis. Hepatology, 73(6), 2326-2341.
25. Li, S., Cheng, C. S., Zhang, C., Tang, G. Y., Tan, H. Y., Chen, H. Y., Wang, N., Lai, A. Y., & Feng, Y.* (2021). Edible and >Herbal Plants for the Prevention and Management of COVID-19. Front Pharmacol, 12, 656103.
26. Xu, Y., Wang, N., Tan, H. Y., Li, S., Zhang, C., Zhang, Z., & Feng, Y.* (2020). Panax notoginseng saponins modulate the gut microbiota to promote thermogenesis and beige adipocyte reconstruction via leptin-mediated AMPKα/STAT3 signaling in diet-induced obesity. Theranostics, 10(24), 11302-11323.
27. Tan, H. Y., Wang, N., Chan, Y. T., Zhang, C., Guo, W., Chen, F., Zhong, Z., Li, S., & Feng, Y.* (2020). ID1 overexpression increases gefitinib sensitivity in non-small cell lung cancer by activating RIP3/MLKL-dependent necroptosis. Cancer Lett, 475, 109-118.
28. Tan, H. Y., Ho, V. W., Chan, Y. T., Zhang, C., Wang, N., Xia, W., & Feng, Y.* (2020). Combination of Gentiana rhodantha and Gerbera anandria in the BL02 formula as therapeutics to non-small cell lung carcinoma acting via Rap1/cdc42 signaling: A transcriptomics/ bio-informatics biological validation approach. Pharmacol Res, 155, 104415.
29. Wang, N., Tan, H. Y., Li, S., Wang, D., Xu, Y., Zhang, C., Xia, W., Che, C. M., & Feng, Y.* (2019). SBP2 deficiency in adipose tissue macrophages drives insulin resistance in obesity. Sci Adv, 5(8), eaav0198.
30. Wang, N., Zhang, C., Xu, Y., Li, S., Tan, H. Y., Xia, W., & Feng, Y.* (2019). OMICs approaches-assisted identification of macrophages-derived MIP-1γ as the therapeutic target of botanical products TNTL in diabetic retinopathy. Cell Commun Signal, 17(1), 81.